Valneva cuts full-year outlook on lower COVID-19 vaccine sales

 

Vaccine developer Valneva on Thursday cut its full-year revenue outlook to account for lower orders of its COVID-19 vaccine after both the European Union and the UK walked away from supply contracts worth more than $1 billion combined.

The French drugmaker, based in southwest France, expects its revenues for the year to reach between 340 million euros and 360 million euros ($369.90 million), against its earlier forecast of 430 million euros and 590 million euros.

https://www.marketscreener.com/quote/stock/VALNEVA-SE-54466/news/Valneva-cuts-full-year-outlook-on-lower-COVID-19-vaccine-sales-41274525/